2025 Half-year financial information
Attachment
Strasbourg (France), December 17, 2025, 17:45 p.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today...
Read MoreStrasbourg, France, 27 November 2025, 00:15 a.m. CET – Transgene (Euronext Paris: TNG) had requested the suspension of trading of its shares (ISIN: FR0005175080) on Euronext Paris as from Wednesday,...
Read More